글로벌 듀센 근이영양증 시장 – 2029년까지의 산업 동향 및 예측

듀센 근이영양증 시장 분석 및 규모

글로벌 듀센 근이영양증 시장은 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 신체 내 디스트로핀 유전자의 결손은 듀센 근이영양증의 주요 원인입니다. 현재 이 질병에 대한 치료법은 없으며 일부 치료법은 제한된 완화 효과만 제공합니다. 그러나 유전자 치료 및 줄기세포 치료 의 주요 발전은 이러한 환자에게 보다 강력한 치료를 제공할 수 있습니다. COVID-19도 시장 성장에 큰 영향을 미쳤습니다.

Data Bridge Market Research는 2022-2029년 예측 기간 동안 듀센 근이영양증 시장의 성장률을 분석합니다. 듀센 근이영양증 시장의 예상 CAGR은 언급된 예측 기간 동안 약 12.3%인 경향이 있습니다. 이 시장은 2021년에 6억 9,334만 달러로 평가되었으며 2029년까지 1,753,820만 달러까지 성장할 것입니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

듀센 근이영양증 시장 범위 및 세분화

Market Definition

Duchenne muscular dystrophy is an inherited disorder that primarily affects the muscle and is considered as an extreme form of muscular dystrophy. It is usually characterised by progressive muscular weakness that leads to wasting of muscle and atrophy of skeletal and heart muscles. There are numerous therapies and drugs to control DMD, though, there is yet no cure for duchenne muscular dystrophy. 

Global Duchenne Muscular Dystrophy Market Dynamics

Drivers

• Increased Use of Corticosteroids

Compared to the several other products, corticosteroids are possibly to emerge as the top-selling products during 2022-2029. By 2029 end, corticosteroids are expected to exceed US$ 9,000 million revenue. Numerous scientific research has found that compared to numerous products to treat duchenne muscular dystrophy, corticosteroids helps to improve muscle strength for up to two to five years, however, long-term benefit of corticosteroids is yet a vague concept.

• Increasing Clinical Research

Currently, more clinical trials are being conducted to assess potential treatments for Duchenne muscular dystrophy. The only approved pharmacological therapy for the management of DMD is an anti-inflammatory regimen based on corticosteroids. In the recent times, there has been a huge increase in the discovery and development of pharmaceutical drugs. Approximately all major companies are now focusing on R&D, possibly leaving a significant impact on the market in the upcoming years.

Opportunities

• Rising R&D and New Drug Approvals

The unmet needs of patients suffering from myelofibrosis are encouraging manufacturers to innovate new solutions. The rising investments in the research and development activities to develop a precise treatment for myelofibrosis is anticipated to boost the growth of the industry in the forecast period. The speedy technological advancements and ongoing clinical trials contribute to industry growth. Other factors such as improved healthcare sector, reimbursement policies, favourable government initiatives, busy lifestyle and changing dietary patterns are also resulting in the industry growth.   

• Varied New Treatments

Among the several treatment types, exon-skipping is holding a great demand. Internal deletions in the gene for dystrophin, a protein critical for preserving the integrity of muscle cell membranes, are the prime cause of Duchenne muscular dystrophy. To allow the remaining exons to come altogether, one therapeutic strategy is to mask an exon that is near to the location wherein the other exons are missing. For instance, in June 2022, Novartis announced, that the European Commission (EC) approved Tabrecta as a monotherapy for treating adults suffering from advanced non-small cell lung cancer (NSCLC) that has mutations that cause exon 14 (METex14) skipping and who require systemic therapy after receiving prior immunotherapy and/or platinum-based chemotherapy.

 Restraints/Challenges

• No cure for the Progressive Disorder

The most common challenge is that DMD is a progressive disorder, which means that the severity of the disease increases over time. Thus, early interventions in the Duchenne muscular dystrophy market, such as those that are used to treat other forms of muscular dystrophy, are not normally effective in treating DMD patients. Moreover, since DMD is a genetic condition, there is no known cure and no trustworthy way to slow or stop the progression of the disease. Thus, it boost the market growth.

• Lack of Awareness

The lack of awareness about the diseased condition and the unavailability of several awareness programs restrict the market growth.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth. The huge drug development and associated processes hamper the market's growth.

This global duchenne muscular dystrophy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global duchenne muscular dystrophy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In September 2022, University of Portsmouth, I-STEM, CNRS, Maj Institute of Pharmacology of the Polish Academy of Sciences, and AFM in France found in a study that  DMD begins much earlier in cells destined to become muscle fibers, known as myoblasts.
• In September 2022, it was found that Eteplirsen is effective in delaying pulmonary reduction in patients with DMD
• In September 2022, researchers from Johns Hopkins Medicine found that experimental drug first developed to treat patients suffering from kidney disease extends survival rate and improves muscle function in mice, genetically engineered to develop a severe form of Duchenne muscular dystrophy (DMD).

Global Duchenne Muscular Dystrophy Market Scope

The global duchenne muscular dystrophy market is segmented on the basis of therapy, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy

• Mutation Suppression
• Exon Skipping Approach

Treatment Type

• Molecular-based Therapies
•  Steroid Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Duchenne Muscular Dystrophy Market Regional Analysis/Insights

The global duchenne muscular dystrophy market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global duchenne muscular dystrophy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for global duchenne muscular dystrophy market throughout the forecasted period due to the increased awareness about the diseases and rapidly disposable income.

North America dominates the market due to the increase prevalence of myelofibrosis (MF), high demand of targeted therapies and advanced healthcare facilities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Duchenne Muscular Dystrophy Market Share Analysis

글로벌 듀센 근이영양증 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 글로벌 듀센 근이영양증 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 듀센 근이영양증 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 파이저 주식회사(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Fresenius Kabi AG(독일)
• 히크마 제약(영국)
• 노바티스 AG(스위스)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• 브리스톨 마이어스 스퀴브 회사(미국)
• GSK 주식회사(영국)
• Bayer AG(독일)
• Sun Pharmaceutical Industries Ltd(인도)
• 베링거인겔하임인터내셔널(독일)
• 사노피(프랑스)
• Sarepta Therapeutics, Inc(영국)
• FibroGen, Inc. (미국)

SKU-54418